- Previous Close
108.50 - Open
103.90 - Bid --
- Ask --
- Day's Range
101.90 - 104.90 - 52 Week Range
95.90 - 136.50 - Volume
1,306 - Avg. Volume
4,320 - Market Cap (intraday)
10.576B - Beta (5Y Monthly) --
- PE Ratio (TTM)
24.76 - EPS (TTM)
4.12 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield 1.45 (1.48%)
- Ex-Dividend Date May 9, 2023
- 1y Target Est
--
BioGaia AB (publ), a healthcare company, develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; Helicobacter pylorithe gastric ulcer bacterium; low bone density; and diverticulitis, as well as baby and child gut, adult gut, immune, pregnancy, oral, and bone health. It offers its products under the BioGaia brand name. The company sells its products through distribution partners or through its own distribution channels. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.
www.biogaia.com212
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 0GTN.IL
View MorePerformance Overview: 0GTN.IL
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0GTN.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0GTN.IL
View MoreValuation Measures
Market Cap
10.27B
Enterprise Value
9.04B
Trailing P/E
29.31
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.25
Price/Book (mrq)
5.99
Enterprise Value/Revenue
6.36
Enterprise Value/EBITDA
16.77
Financial Highlights
Profitability and Income Statement
Profit Margin
34.36%
Return on Assets (ttm)
12.21%
Return on Equity (ttm)
22.82%
Revenue (ttm)
1.27B
Net Income Avi to Common (ttm)
437.42M
Diluted EPS (ttm)
4.12
Balance Sheet and Cash Flow
Total Cash (mrq)
1.45B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
247.83M